...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta‐analysis
【24h】

Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta‐analysis

机译：冠状动脉疾病患者中风预防血清序列：系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose Although clinical trials suggest that colchicine may reduce the risk of vascular events in patients with a history of coronary artery disease, its effect on the prevention of cerebrovascular events still remains unclear. Methods A systematic review and meta‐analysis was performed of all available randomized controlled trials (RCTs) reporting on incident strokes during the follow‐up of patients with a history of cardiovascular disease randomized to colchicine treatment or control (placebo or usual care). Results Four RCTs were identified, including a total of 5553 patients (mean age 61?years, 81% males), with a follow‐up ranging from 1 to 36?months. Colchicine treatment was associated with a significantly lower risk of incident stroke during follow‐up compared to control (risk ratio?0.31, 95% confidence interval 0.13–0.71), without heterogeneity across included studies ( I 2 ?=?0%). Based on the pooled incident stroke rate of control groups (0.9%) in the included RCTs, it was estimated that administration of low‐dose colchicine to 161 patients with coronary artery disease would prevent one stroke during a follow‐up of 23?months. Conclusion Colchicine treatment decreases stroke risk in patients with a history of coronary artery disease. The effect of colchicine in secondary stroke prevention is currently being evaluated in an ongoing RCT.
机译：背景论虽然临床试验表明，血清序可能会降低冠状动脉疾病史上血管事件的风险，但其对预防脑血管事件的影响仍然尚不清楚。方法对患者随机血管疾病历史的后续行动进行系统审查和荟萃分析，对事件中风进行了关于发生的血管疾病历史的后续行动（安慰剂或常规护理）。结果确定了4个RCT，其中共有5553名患者（平均年龄61岁，81％，男性81％），随访范围为1至36个月。数月。与对照（风险率α0.31,95％置信区间0.13-0.71）相比，在随访期间，血清序列治疗与发生后续行程的风险显着降低。基于所包括的RCT中的对照组的汇集入射速率（0.9％），估计将低剂量血清霉素施用至161例冠状动脉疾病患者将在23个月的后续行动期间预防一次中风。结论血氯氨酸处理降低了冠状动脉疾病史患者的中风风险。目前在正在进行的RCT中评估血清序列在次级中风预防中的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号